A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Trial Profile

A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Ibrutinib (Primary) ; Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia; Lymphoid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 May 2016 Status changed from suspended to recruiting.
    • 17 May 2016 Status changed from recruiting to suspended due to CTEP amendment required enrollment to be halted. Amendment is at IRB for review/approval.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top